Status:
RECRUITING
Analysis of Intestinal Microbiota as a Predictor of Response to Treatment of Spondyloarthritis With Biotherapy
Lead Sponsor:
Hôpital Européen Marseille
Conditions:
Spondyloarthritis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Spondyloarthritis (SpA) is a group of inflammatory rheumatic disorders that mainly manifested by inflammatory pain of the spine, pelvis and sometimes limbs. Classically, SpA has been classified into s...
Eligibility Criteria
Inclusion
- For patient with spondyloarthritis:
- Diagnosed for spondyloarthritis or pure axial or axial type psoriatic rheumatism according to Assessment of Spondyloarthritis International Society (ASAS) criteria.
- Requiring treatment with anti-TNFα or anti- IL-17 according to the treatment recommendations of the French Society of Rheumatology (SFR)
- patient not previously treated with biotherapy
- Aged ≥ 18 years
- Having given free and informed written consent
- Being affiliated to the center national security system social
- For control Subject:
- Healthy volunteers without diagnosis of spondyloarthritis or any other chronic disease.
- Aged ≥ 18 years
- Having given free and informed written consent
- Being affiliated with or benefiting from a social security scheme.
Exclusion
- Persons treated with antibiotics, probiotics, prebiotics or any other treatment that may disrupt the gut microbiota within one month before stool sampling.
- Association with another chronic pathology
Key Trial Info
Start Date :
July 16 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 15 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04899154
Start Date
July 16 2019
End Date
May 15 2026
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Européen Marseille
Marseille, France